Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes
Open Access
- 28 May 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (6) , 808
Abstract
Interferon-alpha (IFN-α) is suggested to cause pharmacokinetic drug interactions by lowering expression of drug disposition genes through affecting the activities of nuclear factor kappa B (NF-ĸB) and pregnane X receptor (PXR). The time-resolved impact of IFN-α 2a (1000 U/mL; 5000 U/mL; 2 h to 30 h) on the activities of NF-ĸB and PXR and mRNA expression (5000 U/mL; 24 h, 48 h) of selected drug disposition genes and on cytochrome P450 (CYP3A4) activity in LS180 cells (5000 U/mL; 24 h, 48 h) was evaluated using luciferase-based reporter gene assays, reverse transcription polymerase chain reaction, and luminescence-based CYP3A4 activity assays. The cross-talk between NF-ĸB activation and PXR suppression was evaluated by NF-ĸB blockage (10 µM parthenolide). IFN-α 2a initially (2 h, 6 h) enhanced NF-ĸB activity 2-fold and suppressed PXR activity by 30%. mRNA of CYP3A4 was halved, whereas UGT1A1 was increased (1.35-fold) after 24 h. After 48 h, ABCB1 expression was increased (1.76-fold). CYP3A4 activity remained unchanged after 24 h, but was enhanced after 48 h (1.35-fold). IFN-α 2a demonstrated short-term suppressive effects on PXR activity and CYP3A4 mRNA expression, likely mediated by activated NF-ĸB. Longer exposure enhanced CYP3A4 activity. Clinical trials should evaluate the relevance by investigating the temporal effects of IFN-α on CYP3A4 using a sensitive marker substrate.Keywords
This publication has 45 references indexed in Scilit:
- Immunological Response as a Source to Variability in Drug Metabolism and TransportFrontiers in Pharmacology, 2012
- Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CARAdvanced Drug Delivery Reviews, 2010
- CYP-Mediated Therapeutic Protein-Drug InteractionsClinical Pharmacokinetics, 2010
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Drug Interaction Studies of Therapeutic Proteins or Monoclonal AntibodiesThe Journal of Clinical Pharmacology, 2007
- NF-κB Activation Precedes Increases in mRNA Encoding Neurokinin-1 Receptor, Proinflammatory Cytokines, and Adhesion Molecules in Dextran Sulfate Sodium–Induced Colitis in RatsDigestive Diseases and Sciences, 2005
- Role of cysteine residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potentialLife Sciences, 2004
- Effects of interferon-α on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis CEuropean Journal of Gastroenterology & Hepatology, 1998
- Interferon suppresses erythromycin metabolism in rats and human subjectsHepatology, 1993
- INHIBITION OF THEOPHYLLINE METABOLISM BY INTERFERONThe Lancet, 1987